Natera Acquires Foresight Diagnostics in $450 Million Deal
Transaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.
Read MorePosted by CLP Edit Staff | Dec 8, 2025 | Lymphoma |
Transaction expands Natera’s solid tumor MRD capabilities and adds ultrasensitive phased variant technology with detection below 0.1 parts per million.
Read MorePosted by CLP Edit Staff | Dec 5, 2025 | Analytical Software Systems, Cancer, Molecular Diagnostics |
The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
Read MorePosted by CLP Edit Staff | Dec 2, 2025 | POC Rapid Assays |
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
Read MorePosted by Alyx Arnett | Nov 28, 2025 | Information Technology, Sponsored |
Compare leading liver health management platforms that support early detection, streamline clinical workflows, and improve outcomes for patients with liver disease.
Read MorePosted by CLP Edit Staff | Nov 26, 2025 | Accreditation |
The accreditation covers liver health diagnostics, including Hepatotrack, a molecular diagnostic liquid biopsy that is predictive of acute liver rejection post-liver transplant.
Read More